Farmas USA

Que impresentables, Juanma!!! No van a dar la cara ni te van a devolver lo tuyo. Vete mirando cambio que te la lian una vez y uno ya no sabe cuantas mas pueden caer ... 

SNTA

Del día 16: colocación ATM de Cowen de 100 kilos.

http://phx.corporate-ir.net/phoenix.zhtml?c=147988&p=irol-sec

PLMOUTH MEETING, Pa., Oct. 19, 2015 (GLOBE NEWSWIRE) -- GeneOne Life Science Inc. (KSE:011000), which partnered with Inovio Pharmaceuticals, Inc. (NASDAQ: INO) to develop Inovio’s MERS vaccine (GLS-5300), today announced the filing of an Investigational New Drug Application (IND) for GLS-5300 with the United States Food and Drug Administration. The companies expect to move the MERS vaccine into a phase I clinical trial in healthy volunteers before year end.
http://ir.inovio.com/news/news-releases/news-releases-details/2015/Inovio-and-Partner-Advance-MERS-Vaccine/default.aspx
---
No hay de que preocuparse , todavía en F I
INO vs NVAX

SNTA

Pues solo le falta eso... Igual cualquier día de estos amanece en 5- 6 pavos con la noticia que ha superado la fase 3 de Galaxy-2, pero ahora mismo está como muy parada y depresiva. Optimismo! :-)

Hay muchas farmas estudiando la vacuna contra el Ebola, muchas, ya he perdido la cuenta, aunque me quedo con Merck, JNJ y GSK como las 3 primeras, NVAX es la cuarta en avance de fases ... aunque la primera en calidad de resultados.

NVAX

CYTX

Cytori Therapeutics (CYTX) Enrolls First Patient in SCLERADEC-II Trial

http://www.streetinsider.com/Corporate+News/Cytori+Therapeutics+%28CYTX%29+Enrolls+First+Patient+in+SCLERADEC-II+Trial/10980965.html?si_client=intbro

GNCA

GNCA Suspende sus ensayos sobre la vacuna para la neumonía por los pobres resultados de la Fase 2 del ensayo.
Aclaro que en este ensayo GNCA no usa el coadyuvante Matrix de Novavax sino un coadyuvante de hidróxido de aluminio.
De hecho la empresa anuncia que se van a plantear si para seguir con el programa de la vacuna de la Neumonía deben aumentar la dosis o el coadyuvante. Esos si, imagino que deben empezar de cero, o casi de cero.

http://ir.genocea.com/common/mobile/iphone/releasedetail.cfm?ReleaseID=937136&CompanyID=AMDA-2GAAWE&mobileid=

"We are currently working with our advisors to better understand these results and to determine a next step for this program. While we did not hit statistical significance in this study, the consistent apparent effect gives us confidence in the vaccine concept and in the potential for GEN-004. At this time, we believe it is possible that future trials would require a change in some combination of dose, adjuvant or trial population to confirm any effect," said Chip Clark, pr

GNCA

Pre en -30%

Drug developer Genocea Biosciences Inc said it was suspending the development of a vaccine for pneumonia-causing bacteria after it failed to significantly reduce infection in a mid-stage study.

The company's shares fell 34 percent to $4.75 in premarket trading.

Genocea said it was dropping the development of the vaccine, GEN-004, from its near-term plans to focus on its lead drug - a treatment for genital herpes.

GEN-004 was being developed to fight streptococcus pneumoniae, a type of bacteria that causes a number of infectious diseases including bronchitis, conjunctivitis and brain abscess.

The World Health Organization estimates that up to 1.6 million people, including 800,000 children, die annually from infections caused by the bacteria.

During the trial, which included 98 adults, the vaccine showed consistent reductions in bacterial infection when compared with a placebo, but was not able to achieve statistical significance, the company said.

Genocea has been working on vaccines that target T-cells, a type of white blood cells that protect the body from infectious diseases and cancer.

There are no approved vaccines that work by targeting T-cells.

http://uk.reuters.com/article/2015/10/19/us-genocea-study-idUKKCN0SD1D920151019